Spyre Therapeutics, Inc.
For the period ended May 29, 2025. Filed Jun 2, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 29, 2025 · Filed Jun 2, 2025
Use the contents to explore the available documents and sections.
Contents
Proposal No
Proposal No. 1
The Company’s stockholders elected three Class III directors, Peter Harwin, Michael Henderson, and Sandra Milligan, each to serve until the 2028 Annual Meeting of Stockholders and until their successors are duly elected and qualified.
| Nominees | For | Withheld | Broker Non-Votes |
|---|---|---|---|
| Peter Harwin | 38,196,060 | 7,977,323 | 3,120,432 |
| Michael Henderson, M.D. | 45,441,918 | 731,465 | 3,120,432 |
| Sandra Milligan, M.D., J.D. | 37,612,795 | 8,560,588 | 3,120,432 |
Proposal No. 2
The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.